Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2018

02.05.2018 | Brief Report

A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer

verfasst von: Anuhya Kommalapati, Sri Harsha Tella, Gaurav Goyal, Apar Kishor Ganti, Jairam Krishnamurthy, Pavan Kumar Tandra

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

The role of locoregional treatment (LRT) remains controversial in de novo stage IV breast cancer (BC). We sought to analyze the role of LRT and prognostic factors of overall survival (OS) in de novo stage IV BC patients treated with LRT utilizing the National Cancer Data Base (NCDB). The objective of the current study is to create and internally validate a prognostic scoring model to predict the long-term OS for de novo stage IV BC patients treated with LRT.

Methods

We included de novo stage IV BC patients reported to NCDB between 2004 and 2015. Patients were divided into LRT and no-LRT subsets. We randomized LRT subset to training and validation cohorts. In the training cohort, a seventeen-point prognostic scoring system was developed based on the hazard ratios calculated using Cox-proportional method. We stratified both training and validation cohorts into two “groups” [group 1 (0–7 points) and group 2 (7–17 points)]. Kaplan–Meier method and log-rank test were used to compare OS between the two groups. Our prognostic score was validated internally by comparing the OS between the respective groups in both the training and validation cohorts.

Results

Among 67,978 patients, LRT subset (21,200) had better median OS as compared to that of no-LRT (45 vs. 24 months; p < 0.0001). The group 1 and group 2 in the training cohort showed a significant difference in the 3-year OS (p < 0.0001) (68 vs. 26%). On internal validation, comparable OS was seen between the respective groups in each cohort (p = 0.77).

Conclusions

Our prognostic scoring system will help oncologists to predict the prognosis in de novo stage IV BC patients treated with LRT. Although firm treatment-related conclusions cannot be made due to the retrospective nature of the study, LRT appears to be associated with a better OS in specific subgroups.
Literatur
3.
Zurück zum Zitat Khan SA, Stewart AK, Morrow M (2002) Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 132(4):620–626 (discussion 626–627)CrossRefPubMed Khan SA, Stewart AK, Morrow M (2002) Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 132(4):620–626 (discussion 626–627)CrossRefPubMed
8.
Zurück zum Zitat Fields RC, Jeffe DB, Trinkaus K, Zhang Q, Arthur C, Aft R, Dietz JR, Eberlein TJ, Gillanders WE, Margenthaler JA (2007) Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol 14(12):3345–3351. https://doi.org/10.1245/s10434-007-9527-0 CrossRefPubMed Fields RC, Jeffe DB, Trinkaus K, Zhang Q, Arthur C, Aft R, Dietz JR, Eberlein TJ, Gillanders WE, Margenthaler JA (2007) Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol 14(12):3345–3351. https://​doi.​org/​10.​1245/​s10434-007-9527-0 CrossRefPubMed
10.
Zurück zum Zitat King TA, Lyman J, Gonen M, Reyes S, Hwang E-SS, Rugo HS, Liu MC, Boughey JC, Jacobs LK, McGuire KP, Storniolo AM, Isaacs C, Meszoely IM, Van Poznak CH, Babiera G, Norton L, Morrow M, Wolff AC, Winer EP, Hudis CA (2016) A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). J Clin Oncol 34(15_suppl):1006–1006. https://doi.org/10.1200/JCO.2016.34.15_suppl.1006 CrossRef King TA, Lyman J, Gonen M, Reyes S, Hwang E-SS, Rugo HS, Liu MC, Boughey JC, Jacobs LK, McGuire KP, Storniolo AM, Isaacs C, Meszoely IM, Van Poznak CH, Babiera G, Norton L, Morrow M, Wolff AC, Winer EP, Hudis CA (2016) A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). J Clin Oncol 34(15_suppl):1006–1006. https://​doi.​org/​10.​1200/​JCO.​2016.​34.​15_​suppl.​1006 CrossRef
11.
Zurück zum Zitat Soran A, Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci A, Canturk Z, Utkan Z, Ozaslan C, Evrensel T, Uras C, Aksaz E, Soyder A, Ugurlu UM, Col C, Cabioglu N, Bozkurt B, Sezgin E, Johnson R, Lembersky BC (2016) A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). J Clin Oncol 34(15_suppl):1005–1005. https://doi.org/10.1200/JCO.2016.34.15_suppl.1005 CrossRef Soran A, Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci A, Canturk Z, Utkan Z, Ozaslan C, Evrensel T, Uras C, Aksaz E, Soyder A, Ugurlu UM, Col C, Cabioglu N, Bozkurt B, Sezgin E, Johnson R, Lembersky BC (2016) A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). J Clin Oncol 34(15_suppl):1005–1005. https://​doi.​org/​10.​1200/​JCO.​2016.​34.​15_​suppl.​1005 CrossRef
Metadaten
Titel
A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer
verfasst von
Anuhya Kommalapati
Sri Harsha Tella
Gaurav Goyal
Apar Kishor Ganti
Jairam Krishnamurthy
Pavan Kumar Tandra
Publikationsdatum
02.05.2018
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4802-2

Weitere Artikel der Ausgabe 3/2018

Breast Cancer Research and Treatment 3/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.